Articles related to PARP INHIBITORS

Talazoparib plus enzalutamide reduced the risk of radiographic progression or death by 52% versus enzalutamide alone in patients with metastatic castration-sensitive prostate cancer harboring homologous recombination repair gene alterations, with a 3-year rPFS rate of 77% versus 56% in a 599-patient phase 3 trial.

An ESMO express update to epithelial ovarian cancer guidelines added rucaparib and mirvetuximab soravtansine as treatment options, but expert commentary and two subsequent FDA approvals have raised questions about the update’s current clinical applicability.

Adding niraparib to abiraterone prolonged radiographic progression-free survival in BRCA-mutant metastatic hormone-sensitive prostate cancer, with overall survival data still maturing.

These results suggest that PARP inhibition represents a potential treatment strategy in HRR-deficient advanced biliary tract cancer, including the potential platform to investigate novel combination treatment strategies as well as consideration for a more selective biomarker selection.

The results of PROfound and PROpel underscore the importance of identifying the genomic characteristics of the patient and the cancer to guide the selection of the most appropriate treatment for a specific patient type.